

# **Arecor Therapeutics**

## Second in-house Specialty Hospital deal

Arecor's co-development and exclusive licence option agreement with a leading global medical products company demonstrates further strategic execution in securing revenue generating partnerships for its proprietary portfolio of Specialty Hospital products. It also further validates the attractiveness and relevance of its Arestat formulation expertise in developing novel products, the first of which (biosimilar AT220) was launched earlier this year. Specialty Hospital licensing agreements form a key part of Arecor's mid-term growth prospects, and while these are typically associated with limited disclosure, prior Trinity Delta analysis provides a framework for assessing the potential value. Near-term, Arecor's investment case remains centred on its diabetes franchise, with further AT278 Phase I data anticipated during H124. Our valuation is updated to £179m, or 583p per share.

Year-end: December 31	2021	2022	2023E	2024E
Revenues (£m)	1.2	2.4	4.8	7.1
Adj. PBT (£m)	(7.1)	(11.7)	(10.3)	(9.1)
Net Income (£m)	(6.2)	(9.1)	(8.3)	(7.9)
EPS (p)	(0.3)	(0.3)	(0.3)	(0.3)
Cash (£m)	18.3	12.8	5.8	1.0
EBITDA (£m)	(6.3)	(10.2)	(8.5)	(8.0)

Source: Trinity Delta Note: Adjusted numbers exclude share-based payments and exceptionals.


- Specialty Hospital deal with unnamed global player This licensing deal covers a high value, Arestat-enabled ready-to-dilute (RTD) formulation of a blockbuster oncology product. Deal economics are also undisclosed, although Arecor is eligible for potential milestones in connection with further co-development and regulatory work, plus milestones and royalties should the unnamed partner exercise its option to an exclusive worldwide development and commercialisation licence.
- Formulation expertise provides value-add A key challenge with Specialty Hospital products is the lack of stable liquid formulations. Many injectable products used within hospitals require some form of preparation (eg reconstitution or dilution) which has time, cost, and safety implications for patients, physicians, and payers. Formulation improvements can include ready-to-administer (RTA), ready-to-use (RTU), and RTD versions. Arecor's first Specialty Products licence covered Hikma's AT307, an undisclosed RTU formulation. This second deal is for a stable liquid RTD formulation of a lyophilised powder product with a complex reconstitution process.
- Growth prospects becoming clearer Our November 2023 Outlook provided a framework for assessing the cash flows from existing, and new, Specialty Hospital product licences. Upfront payments and pre-commercial milestones should limit Arecor's at-risk spend, with a profitable return from downstream commercial payments/royalties. While not from a Specialty Hospital product, first royalties will be recorded in FY23, following the European launch of biosimilar AT220.
- Valuation updated to £179m, or 583p per share Our Arecor valuation has been raised to £179m, or 583p per share (from £176m and 575p) with incorporation of this deal. Continued clinical progress, notably with AT278 and AT247, and execution of further partnerships, could result in material upside revisions.

## Update

Yes

7 December 2023

Price	190.00p
Market Cap	£58.2m
Enterprise Value	£52.4m
Shares in issue	30.6m
12-month range	175p-322p
Free float	34.2%
Primary exchange	AIM London
Other exchanges	N/A
Sector	Healthcare
Company Code	AREC



#### **Company description**

Corporate client

Arecor Therapeutics is a revenuegenerating clinical stage drug developer, with a well-balanced portfolio of in-house and partnered programmes. Its proprietary Arestat formulation platform results in enhanced products with lower development risks and less onerous regulatory approvals.

#### Analysts

#### Lala Gregorek

lgregorek@trinitydelta.org +44 (0) 20 3637 5043

#### Philippa Gardner

pgardner@trinitydelta.org +44 (0) 20 3637 5042



# **Arecor: Specialty Hospital deal momentum builds**

Arecor's track record in overcoming complex formulation challenges is becoming more widely appreciated as it secures licencing deals and technology partnerships with leading global companies. Through exploiting its proprietary Arestat platform and formulation expertise Arecor has created a portfolio of inhouse and partnered programmes with otherwise unachievable enhanced clinical properties. This broad and well-balanced pipeline of innovative products offers similar milestone and royalty streams to classic drug discovery plays yet has lower development risks, and a less costly and more rapid route to market. We continue to view the emerging diabetes franchise as having the most valuation upside potential, with the competitive profiles of lead assets AT278 (ultra-concentrated, ultra-rapid insulin) and AT247 (ultra-rapid pump-optimised insulin) well suited to the changing diabetes landscape. Mid-term, the in-house Specialty Hospital portfolio could generate meaningful future income streams as further deals and partnerships are signed, with each product requiring limited atrisk spend. Pre-commercial deal milestones should offset these costs, with a return on investment from subsequent royalties (or other payments). Our updated Arecor valuation is £179m, equivalent to 583p a share.

Second Specialty Hospital deal with a leading global medical products company...

...for a RTD formulation of a blockbuster oncology product

### Details are limited but the market size exceeds our base case assumptions


Arecor's co-development and exclusive licence option agreement with a leading global medical products company is the second licensing deal it has signed on a proprietary Specialty Hospital programme. In this case, the Arestat technology and expertise has been applied to develop a stable liquid ready-to-dilute (RTD) formulation of a lyophilised powder with a complex reconstitution process. The identity of the partner, product, and precise deal terms are undisclosed. However, as the valuation framework detailed in our <u>November 2023 Outlook</u> shows, while undoubtedly helpful, these details are not strictly necessary in modelling nor ascribing a valuation to the cash flows from such deals (discussed below).

Arecor's in-house formulation work on its proprietary Specialty Hospital pipeline has focused on creating stable liquid formulations of existing hospital-based injectable products that require preparation (eg reconstitution or dilution) before use. These formulations may be ready-to-administer (RTA), ready-to-use (RTU), or ready-to-dilute (RTD) versions, which all have the potential to confer time, cost, quality, ease of use, and safety benefits for patients, physicians, and payers. The product underlying this latest deal is a RTD reformulation of an undisclosed blockbuster oncology product that requires lengthy and complex reconstitution.

Our base case assumptions for a typical product (Exhibit 1) are for Arecor's R&D investment pre-deal (typically over two to three years) to be at least fully recouped via upfronts and milestones by product launch (around three years post deal), with royalties on sales then generating a profitable return. We assume peak sales are achieved around three years post-launch, with peak royalties ranging from c £1m to c £11m per annum (based on market sizes up to \$300m, peak sales of \$20-80m and a 5-15% royalty). While we assume that Arecor will seek to develop the more commercially relevant opportunities, for the purposes of assessing the unpartnered Specialty Hospital products, our base case is that most will be around \$40-50m in peak sales for peak royalties of £4m per annum, in-line with our typical conservative stance.



#### **Exhibit 1: Illustrative Specialty Hospital product**



Source: Trinity Delta. Note: Arecor investment and milestone income estimates are cumulative over time; royalty range is based on royalties of 5-15% on peak sales of \$20-80m

We note that several large companies are active in the hospital products market and have indicated that they are interested in collaborations to improve and extend their product portfolios. These include Baxter, Fresenius Kabi, Hikma, Pfizer, Sandoz, and Teva which together encompass a wide range of products/areas including biosimilars, complex biologics and generics. Indeed, Arecor's first Specialty Products licence was with Hikma for AT307, an undisclosed RTU formulation of a marketed injectable.

As also covered in our <u>November 2023 Outlook</u>, due to Arecor's greater value contribution translating into more meaningful milestones and higher royalty rates, the licensing deals for proprietary programmes should prove more lucrative than technology partnerships which centre on reformulation of the partner's own product. The first commercial Arestat-enabled product to launch, biosimilar AT220 (<u>November 2023 Lighthouse</u>), is an example of the latter. Pre-commercial technology partnerships are also in place with several other undisclosed and named companies, including Intas, Par Pharmaceuticals and Eli Lilly. We note that Arecor recently signed a further collaboration agreement with Lilly.

The additional validation provided by the latest Specialty Hospital product deal provides us with increasing comfort around Arecor's ability to continue to identify, formulate, and develop internal programmes that are attractive to larger partners. Arecor's focus is on serious infections, cancer, and emergency care, with likely around three to five under active development at any one time. Thus, we believe that the partnering strategy for Specialty Hospital products should be sustainable and develop into a potential fruitful source of future income.

he Near-term, we continue to view the in-house diabetes programmes as the main value driver for Arecor, with the greatest upside potential. The clinical data to date (December 2022 Outlook) from the two lead diabetes assets, AT278 (ultra-concentrated rapid insulin) and AT247 (ultra-rapid insulin), suggest competitive profiles well suited to the changing diabetes landscape in terms of demography and the technological advances in treatment. Specifically, this includes addressing the needs of novel insulin pump delivery systems which require precise absorption profiles that are more rapid and highly consistent. Further AT278 Phase I clinical data are anticipated during H124.

### Several large companies are involved in the hospital products market

# Lilly technology partnership was recently extended

Deal execution will be key to realising value from the Specialty Hospital portfolio

Diabetes franchise remains the key value driver



# Valuation and Financials

Updated Arecor valuation of £179m, equivalent to 583p per share

We value Arecor using a rNPV (risk-adjusted net present value) model, including the diabetes franchise, partnered assets, and the in-house Specialty Hospital research portfolio. More details on our valuation methodology are available in our recent note (<u>November 2023 Outlook</u>). Following incorporation of the latest Specialty Hospital deal, outlined below, plus rolling forwards in time and updating net cash, our valuation is increased to £179m, equivalent to 583p per share (from £176m and 575p/share). An overview of our valuation and key assumptions is summarised in Exhibit 2.

Programme	NPV	NPV	Success	Royalty	rNPV	rNPV	rNPV/	Notes
	(£m)	(\$m)	probability		(£m)	(\$m)	share (p)	
Diabetes franchise	253.4	304.1	60%	High single to	117.2	140.6	382.7	Peak sales: c \$875m;
(AT278 and AT247)				double-digit				Launch year: 2026+
Research	39.8	47.8	Various	High single to	11.7	14.1	38.3	Various with peak
(Specialty Hospital)			(10-40%)	double-digit				sales of \$20-80m;
								Launch year: 2026+
<b>AT307</b> (Hikma)	26.2	31.5	80%	High single to	19.8	23.8	64.7	Peak sales: \$65m;
(Specialty Hospital)				double-digit				Launch year: 2026
Not disclosed	20.1	24.1	60%	High single to	12.1	14.5	39.4	Peak sales: \$65m;
(Specialty Hospital)				double-digit				Launch year: 2027+
AT220 (undisclosed	12.8	15.4	95%	Low single	11.3	13.5	36.8	Peak sales: \$500m;
biosimilar - partnered)				digit				Launch year: 2023
AT292/INBRX-101	20.4	24.4	50%	Low single	9.7	11.7	31.8	Peak sales: \$515m;
(AATD - Inhibrx)				digit				Launch year: 2026
Tetris Pharma/Ogluo	7.8	9.3	100%	N/A	7.8	9.3	25.4	Peak sales: \$10m;
								Launch year: 2021
Operating costs	(16.8)	(20.2)			(16.8)	(20.2)	(55.0)	
Net cash	5.8	7.0			5.8	7.0	19.0	
Total	369.5	443.4			178.6	214.4	583.2	

#### Exhibit 2: Arecor rNPV valuation

Source: Trinity Delta based on a 12.5% discount factor and £/\$ FX rate of 1.20. Note: AATD = Alpha-1 antitrypsin deficiency.

Within our updated valuation, we have broken out the RTD oncology formulation as a standalone contribution, separate to the Specialty Hospital rNPV, as this is now being developed with a partner. As information is limited, we apply our Specialty Hospital framework, including launch at least three years post deal ie 2027+, and a rapid three-year ramp to peak sales. We conservatively estimate these at \$65m (above our typical base case) based on the blockbuster nature of the reference product. However, we assume this will be off-patent by the time of launch, therefore reducing the market value through price discounting, while also increasing competition. We include flat royalties of c 10%, and only include a limited number of modest future milestones.

## Maintain a conservative approach, based on the Specialty Hospital framework

Partnering deal prompts a

undisclosed asset

standalone valuation of the

There could be upside to both our peak sales and royalties/downstream payments, particularly on the former if the partner is able to drive higher market share and/or more of the market size is maintained, whilst the co-development nature of the deal may confer higher royalties and/or downstream milestones than our current assumptions. As the product is now partnered, we assign a 60% probability of success. The higher-than-average peak sales, plus the increased



Upside on Specialty Hospital rNPV as deals are executed...

...whilst diabetes remains the main value driver

# Cash should be sufficient to execute current strategic plans

probability on the standalone asset, means the rNPV is higher than it had been within the previous Specialty Hospital rNPV ie the Specialty Hospital rNPV has decreased by less than the value of the standalone asset.

The remaining Specialty Hospital rNPV of £12m, which is largely a conservative placeholder, consists of a blend of assets based on the framework outlined in our <u>November 2023 Outlook</u>, with various launch timelines and probabilities. We assume a steady flow of new assets into the portfolio, and as seen with the latest deal, there is upside as partnerships are executed.

As a reminder, the diabetes franchise (consisting largely of AT278 and AT247) remains the main value driver for Arecor and there could be material upside as development progresses and data become available. The partnered and commercial assets together could represent a meaningful source of future income with potential upside on AT220 launch in the US, as the royalty builds and/or the partner/product is disclosed/identified. We do not attribute a value to the technology formulation development collaborations, nor do we provide an indicative valuation of the Arestat technology platform.

Our financial forecasts, which are unchanged, are shown in Exhibit 3. As a reminder, Arecor had cash and equivalents (including short-term investments) at end-June 2023 of £8.2m and post period end also received £0.4m in grants and £1.3m in R&D tax credits. Our model suggests that Arecor has sufficient funds to execute on current strategic plans, including the ongoing Phase I trial of AT278, and to provide optionality into 2024 to prepare for potential future development plans as these are refined. Our forecasts do not assume any potential conversion(s) of pre-licence technology partnerships to longer-term licence agreements, nor any significant uncertain milestones. Hence partnering and/or licence income from upfront payments, development milestones, or higher revenues from product sales and royalties, could all extend the runway.

## **Exhibit 3: Summary of financials**

Year-end: Dec 31	£'000s	2020	2021	2022	2023E	2024E
INCOME STATEMENT						
Revenues		1,698	1,158	2,403	4,805	7,057
Cost of goods sold		0	0	0	0	0
Gross Profit		1,698	1,158	2,403	4,805	7,057
R&D expenses		(3,937)	(5,386)	(8,613)	(5,857)	(6,150)
SG&A expenses		(1,642)	(2,389)	(5,381)	(9,010)	(9,472)
Underlying operating profit		(3,880)	(6,617)	(11,591)	(10,063)	(8,564)
Share-based payments		(318)	(484)	(503)	(523)	(539)
Exceptionals		0	(462)	(171)	0	0
Other revenue/expenses		452	640	1,132	925	103
EBITDA		(3,259)	(6,268)	(10,289)	(8,541)	(7,961)
Operating Profit		(3,428)	(6,439)	(10,630)	(9,137)	(8,462)
Financing costs/income		(84)	(21)	88	272	29
Profit Before Taxes		(3,512)	(6,945)	(10,542)	(8,866)	
Adj. PBT		(4,283)	(7,122)		(10,314)	
Current tax income		760	776	1,282	527	553
Net Income		(2,752)	(6,169)	(9,260)	(8,339)	(7,879)
EPS (p)		(0.2)	(0.3)	(0.3)	(0.3)	(0.3)
Adj. EPS		(0.2)	(0.3)	(0.4)	(0.3)	(0.3)
DPS (p)		0.0	0.0	0.0	0.0	0.0
Average no. of shares (m)		16.2	23.0	28.9	30.6	30.8
Gross margin		100%	100%	100%	100%	100%
BALANCE SHEET						
Current assets		3,822	20,515	17,477		7,859
Cash and cash equivalents		2,898	18,316	4,765	5,826	1,023
Short-term investments		0	0	8,041	0	0
Accounts receivable		166	1,423	2,215	4,212	4,060
Inventories		0	0	1,131	1,556	1,632
Other current assets		758	776	1,325	1,136	1,143
Non-current assets		462	406	4,288	4,011	3,857
Property, plant & equipment		375 38	328 30	838	722 3,242	693 3,116
Intangible assets		38 48	30 48	3,402 48	3,242 48	3,118 48
Other non-current assets Current liabilities		(1,408)	( <b>2</b> , <b>267</b> )	(3,728)	(6,645)	(7,459)
Short-term debt		(1,400)	(2,207)	(3,720)	(0,043)	(7,457) 0
Accounts payable		(1,303)	(2,141)	(3,526)	(6,443)	(7,257)
Other current liabilities		(1,000)	(126)	(202)	(202)	(202)
Non-current liabilities		(2,102)	(105)	(582)	(458)	(458)
Long-term debt		(1,698)	(103)	(302)	(430)	(450)
Other non-current liabilities		(403)	(105)	(582)	(458)	(458)
Equity		774	18,549	17,455	9,639	3,799
CASH FLOW STATEMENTS						
Operating cash flow		(1,857)	(5,450)	(10,780)	(6,536)	(5,956)
Profit before tax		(3,512)	(6,945)	(10,542)	(8,866)	(8,432)
Non-cash adjustments		614	1,156	687		1,010
Change in working capital		747	(419)	(1,659)	494	890
Interest paid		0	0	0	272	29
Taxes paid		295	758	734	716	547
Investing cash flow		(49)	(68)	(7,993)	7,721	(347)
CAPEX		(52)	(69)	(345)	(320)	(347)
Acquisitions/disposals		0	0	284	0	0
Other investing cash flows		3	1	(7,932)	8,041	0
Financing cash flow		1,774	20,931	5,160	(124)	1,500
Proceeds from equity		0	18,565	5,648	0	1,500
Increase in loans		1,840	2,500	0	0	0
Other financing cash flow		(67)	(134)	(488)	(124)	0
Net increase in cash		(132)	15,413	(13,613)		(4,803)
Cash at start of year		3,074	2,898	18,316	4,765	5,826
Cash at end of year		2,898	18,316	4,765	5,826	1,023
Net cash at end of year		1,200	18,316	12,806	5,826	1,023
Source: Company, Trinity Del	ta. Note: FY24	e R&D is larg	elv illustra	ative pend	ling devel	opment pla

Source: Company, Trinity Delta. Note: FY24e R&D is largely illustrative pending development plans



Philippa Gardner

Lala Gregorek

Franc Gregori

pgardner@trinitydelta.org +44 (0) 20 3637 5042

lgregorek@trinitydelta.org +44 (0) 20 3637 5043

fgregori@trinitydelta.org +44 (0) 20 3637 5041

#### Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2023 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org